Clinical trial
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not…
NCT00004026 · CTI BioPharma, Industry · Terminated
Key facts
| NCT number | NCT00004026 |
|---|---|
| Title | CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy |
| Official title | A Phase II Study of CT-2584 Mesylate in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | CT-2584, chemotherapy |
| Enrollment | 80 |
| Start date | Dec 1, 1998 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Aug 27, 2004 |
| Last update posted | Oct 19, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: